Literature DB >> 26055920

A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.

Yihua Xu1, Xiaofeng Zhou, Brandon T Suehs, Abraham G Hartzema, Michael G Kahn, Yola Moride, Brian C Sauer, Qing Liu, Keran Moll, Margaret K Pasquale, Vinit P Nair, Andrew Bate.   

Abstract

INTRODUCTION: An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs and analytic tools affect usability and interpretation of results.
METHODS: Humana claims data from 2007 to 2012 were mapped to Observational Medical Outcomes Partnership (OMOP) and Mini-Sentinel CDMs. Data were described and compared at the patient level by source code and mapped concepts. Study cohort construction and effect estimates were also compared using two different analytical methods--one based on a new user design implementing a high-dimensional propensity score (HDPS) algorithm and the other based on univariate self-controlled case series (SCCS) design--across six established positive drug-outcome pairs to learn how differences in CDMs and analytics influence steps in the database analytic process and results.
RESULTS: Claims data for approximately 7.7 million Humana health plan members were transformed into the two CDMs. Three health outcome cohorts and two drug cohorts showed differences in cohort size and constituency between Mini-Sentinel and OMOP CDMs, which was a result of multiple factors. Overall, the implementation of the HDPS procedure on Mini-Sentinel CDM detected more known positive associations than that on OMOP CDM. The SCCS method results were comparable on both CDMs. Differences in the implementation of the HDPS procedure between the two CDMs were identified; analytic model and risk period specification had a significant impact on the performance of the HDPS procedure on OMOP CDM.
CONCLUSIONS: Differences were observed between OMOP and Mini-Sentinel CDMs. The analysis of both CDMs at the data model level indicated that such conceptual differences had only a slight but not significant impact on identifying known safety associations. Our results show that differences at the ecosystem level of analyses across the CDMs can lead to strikingly different risk estimations, but this can be primarily attributed to the choices of analytic approach and their implementation in the community-developed analytic tools. The opportunities of using CDMs are clear, but our study shows the need for judicious comparison of analyses across the CDMs. Our work emphasizes the need for ongoing efforts to ensure sustainable transparent platforms to maintain and develop CDMs and associated tools for effective safety surveillance.

Entities:  

Mesh:

Year:  2015        PMID: 26055920     DOI: 10.1007/s40264-015-0297-5

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  20 in total

1.  A policy framework for public health uses of electronic health data.

Authors:  Deven McGraw; Kristen Rosati; Barbara Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 2.  A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data.

Authors:  Gary Schneider; Sumesh Kachroo; Natalie Jones; Sheila Crean; Philip Rotella; Ruzan Avetisyan; Matthew W Reynolds
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 3.  Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages.

Authors:  Samy Suissa; Edeltraut Garbe
Journal:  Nat Clin Pract Rheumatol       Date:  2007-12

4.  Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.

Authors:  Sengwee Toh; Jerry Avorn; Ralph B D'Agostino; Jerry H Gurwitz; Bruce M Psaty; Kenneth J Rothman; Kenneth G Saag; Miriam C J M Sturkenboom; Jan P Vandenbroucke; Almut G Winterstein; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-08-07       Impact factor: 2.890

5.  The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Authors:  Christian G Reich; Patrick B Ryan; Marc A Suchard
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  The methodology of self-controlled case series studies.

Authors:  Heather J Whitaker; Mounia N Hocine; C Paddy Farrington
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

7.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

8.  Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Authors:  Joshua J Gagne; Jeremy A Rassen; Alexander M Walker; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

Review 9.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.

Authors:  Preciosa M Coloma; Paul Avillach; Francesco Salvo; Martijn J Schuemie; Carmen Ferrajolo; Antoine Pariente; Annie Fourrier-Réglat; Mariam Molokhia; Vaishali Patadia; Johan van der Lei; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Drug Saf       Date:  2013-01       Impact factor: 5.606

View more
  19 in total

1.  Common Models, Different Approaches.

Authors:  Joshua J Gagne
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

2.  Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system.

Authors:  Jeffrey S Brown; Judith C Maro; Michael Nguyen; Robert Ball
Journal:  J Am Med Inform Assoc       Date:  2020-05-01       Impact factor: 4.497

3.  Evaluating common data models for use with a longitudinal community registry.

Authors:  Maryam Garza; Guilherme Del Fiol; Jessica Tenenbaum; Anita Walden; Meredith Nahm Zozus
Journal:  J Biomed Inform       Date:  2016-10-29       Impact factor: 6.317

4.  Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.

Authors:  Yu Yang; Xiaofeng Zhou; Shuangqing Gao; Hongbo Lin; Yanming Xie; Yuji Feng; Kui Huang; Siyan Zhan
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

5.  Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records.

Authors:  Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter
Journal:  Appl Clin Inform       Date:  2019-05-08       Impact factor: 2.342

6.  Transformation and Evaluation of the MIMIC Database in the OMOP Common Data Model: Development and Usability Study.

Authors:  Nicolas Paris; Adrien Parrot; Antoine Lamer
Journal:  JMIR Med Inform       Date:  2021-12-14

Review 7.  Machine Learning in Causal Inference: Application in Pharmacovigilance.

Authors:  Yiqing Zhao; Yue Yu; Hanyin Wang; Yikuan Li; Yu Deng; Guoqian Jiang; Yuan Luo
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

8.  An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.

Authors:  Hyunah Shin; Suehyun Lee
Journal:  BMC Med Inform Decis Mak       Date:  2021-05-17       Impact factor: 2.796

9.  Big Data: transforming drug development and health policy decision making.

Authors:  Demissie Alemayehu; Marc L Berger
Journal:  Health Serv Outcomes Res Methodol       Date:  2016-03-05

10.  Predicting Future Cardiovascular Events in Patients With Peripheral Artery Disease Using Electronic Health Record Data.

Authors:  Elsie Gyang Ross; Kenneth Jung; Joel T Dudley; Li Li; Nicholas J Leeper; Nigam H Shah
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.